Alkermes buys pulmonary drug system manufacturer AIR (Advanced Inhalation Research)
This article was originally published in Clinica
Drug delivery company Alkermes has bought the privately-held Advanced Inhalation Research (AIR), which develops dry-powder pulmonary drug delivery systems, in a share transaction valued at around $115 million.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.